S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Daré Bioscience (DARE) Stock Forecast, Price & News

+0.01 (+0.87%)
(As of 05/27/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.02 million shs
Average Volume
1.81 million shs
Market Capitalization
$98.26 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive DARE News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Daré Bioscience logo

About Daré Bioscience

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.36 per share


Net Income
$-38.70 million
Pretax Margin




Free Float
Market Cap
$98.26 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.81 out of 5 stars

Medical Sector

803rd out of 1,424 stocks

Pharmaceutical Preparations Industry

391st out of 681 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Daré Bioscience (NASDAQ:DARE) Frequently Asked Questions

Is Daré Bioscience a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Daré Bioscience stock.
View analyst ratings for Daré Bioscience
or view top-rated stocks.

When is Daré Bioscience's next earnings date?

Daré Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Daré Bioscience

How were Daré Bioscience's earnings last quarter?

Daré Bioscience, Inc. (NASDAQ:DARE) issued its quarterly earnings data on Thursday, March, 31st. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.03. During the same period in the previous year, the company earned ($0.22) earnings per share.
View Daré Bioscience's earnings history

What price target have analysts set for DARE?

4 Wall Street analysts have issued 12-month price targets for Daré Bioscience's stock. Their forecasts range from $4.00 to $17.00. On average, they anticipate Daré Bioscience's stock price to reach $9.00 in the next year. This suggests a possible upside of 675.9% from the stock's current price.
View analysts' price targets for Daré Bioscience
or view top-rated stocks among Wall Street analysts.

Who are Daré Bioscience's key executives?
Daré Bioscience's management team includes the following people:
  • Ms. Sabrina Martucci Johnson, Pres, CEO, Sec. & Director (Age 55, Pay $563.74k)
  • Ms. Lisa Walters-Hoffert, Chief Financial Officer (Age 63, Pay $400.32k)
  • Mr. John A. Fair, Chief Strategy Officer (Age 50, Pay $453.61k)
  • Mr. Mark Walters, VP of Operations (Age 67)
  • Dr. David Friend, Chief Scientific Officer
What other stocks do shareholders of Daré Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).

What is Daré Bioscience's stock symbol?

Daré Bioscience trades on the NASDAQ under the ticker symbol "DARE."

Who are Daré Bioscience's major shareholders?

Daré Bioscience's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.11%), BlackRock Inc. (0.72%), State Street Corp (0.21%), GSA Capital Partners LLP (0.15%), Renaissance Technologies LLC (0.12%) and Buckingham Strategic Partners (0.04%).
View institutional ownership trends for Daré Bioscience

Which institutional investors are selling Daré Bioscience stock?

DARE stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP.
View insider buying and selling activity for Daré Bioscience
or view top insider-selling stocks.

Which institutional investors are buying Daré Bioscience stock?

DARE stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Renaissance Technologies LLC, Citigroup Inc., Bank of New York Mellon Corp, Buckingham Strategic Partners, and State Street Corp.
View insider buying and selling activity for Daré Bioscience
or or view top insider-buying stocks.

How do I buy shares of Daré Bioscience?

Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Daré Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $1.16.

How much money does Daré Bioscience make?

Daré Bioscience has a market capitalization of $98.26 million. The biotechnology company earns $-38.70 million in net income (profit) each year or ($0.64) on an earnings per share basis.

How many employees does Daré Bioscience have?

Daré Bioscience employs 16 workers across the globe.

What is Daré Bioscience's official website?

The official website for Daré Bioscience is www.darebioscience.com.

How can I contact Daré Bioscience?

Daré Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company can be reached via phone at (858) 926-7655, via email at [email protected], or via fax at 617-494-1544.

This page was last updated on 5/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.